As Smac mimetics have been shown to be well-tolerated in early clinical trials [11, 12], IFNγ and Smac mimetic combination therapy merits further investigation and may present a promising novel apoptosis targeted regimen for a subgroup of lung cancer cells with biomarkers to predict responses. The gene discussed is IFNG; the disease is lung carcinoma.